Risk factor
Very poor trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Original BioMedicals Co., Ltd. is a biotechnology company focused on creating novel chemical compounds to fulfill critical medical requirements, with an initial emphasis on the healthcare landscape in Taiwan. Its current product pipeline encompasses several key developments: Radprotect (A01): A pre-clinical stage compound designed to offer protection against radiation exposure. CCM-Ami (A02): Engineered to shield healthy tissues from the damaging side effects of both chemotherapy drugs and ionizing radiation. GLP-1 CCM (P01): A therapeutic agent developed for the management of type 2 diabetes. The firm was established in 2011 and operates from its base in Taipei, Taiwan.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.